Skye Bioscience (SKYE) Non Operating Income (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Non Operating Income of $165005.0 for Q1 2026, down 74.93% year-over-year from $658243.0 in Q1 2025, and down 63.62% quarter-over-quarter from $453581.0 in Q4 2025.
Skye Bioscience (SKYE) Non Operating Income (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Non Operating Income for 12 consecutive years, with $165005.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 74.93% year-over-year to $165005.0; the TTM figure through Mar 2026 stood at $1.8 million (down 44.58% YoY), while the FY2025 annual figure was $2.2 million, down 38.27% from the prior year.
- Non Operating Income slipped to $165005.0 in Q1 2026 per SKYE's latest filing, from $453581.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $1.1 million in Q1 2024 and bottomed at -$2.1 million in Q1 2023.
- Historically, Non Operating Income has averaged $116216.9 across 5 years, with a median of $165005.0 in 2026.
- Annual changes were most pronounced in 2022 — Non Operating Income tumbled 3490.84% — and 2024, when it surged 545.91%.
- Skye Bioscience's Non Operating Income stood at -$606972.0 in 2022, then surged by 45.03% to -$333673.0 in 2023, then jumped by 375.61% to $919622.0 in 2024, then sank by 50.68% to $453581.0 in 2025, then tumbled by 63.62% to $165005.0 in 2026.
- Business Quant data shows SKYE's Non Operating Income at $165005.0 in Q1 2026, $453581.0 in Q4 2025, and $509874.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -53.64 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -51.63 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - | 278,109.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 165,005.00 |
| Dec 31, 2025 | 453,581.00 |
| Sep 30, 2025 | 509,874.00 |
| Jun 30, 2025 | 622,453.00 |
| Mar 31, 2025 | 658,243.00 |
| Dec 31, 2024 | 919,622.00 |
| Sep 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 510,826.00 |
| Mar 31, 2024 | 1.13 Mn |
| Dec 31, 2023 | -333,673.00 |
| Sep 30, 2023 | -240,068.00 |
| Jun 30, 2023 | -264,903.00 |
| Mar 31, 2023 | -2.07 Mn |
| Dec 31, 2022 | -606,972.00 |
| Sep 30, 2022 | -205,001.00 |
| Jun 30, 2022 | -195,777.00 |
| Mar 31, 2022 | -155,378.00 |
| Dec 31, 2021 | -50,650.00 |
| Sep 30, 2021 | -5,709.00 |
| Jun 30, 2021 | -192,753.00 |